Amati AIM VCT plc
Annual Report & Financial Statements 2023
9
Information for Shareholders
Financial Statements
Reports from the Directors
Strategic Report
Highlights
Foundry” games publishing label. Polarean, a medical
imaging company, fell 31% over the year. Polarean has
been developing a clinically transformational lung
imaging technology, however its regulatory submission
fell foul of FDA delays caused by the pandemic which
were still being felt in 2022. The FDA is majority funded
by the US government and is assessed by the number
of on-time decisions. Where they might miss a deadline,
the FDA can either delay a decision or issue a complete
response letter (CRL). Delays are the FDA’s responsibility,
but CRLs are the application sponsor’s responsibility. It is
no coincidence that in 2022 the number of CRLs reached
new heights as a proportion of FDA approvals at more
than 30%. Polarean received final approval in December
2022 more than a year after its original decision date,
with the delay having a significant impact on its
commercial plan and cash reserves. GB Group, a
specialist in digital location, identity verification and fraud
software, fell 46% in the period after a solid pandemic
performance. There was continued fallout from the
poorly received acquisition of Acuant, a specialist in
biometric and document verification. In addition, activity
in cryptocurrency identity verification fell away as
sentiment soured, while the highly publicised bankruptcy
of the FTX crypto exchange brought the risks in this area
into sharp relief. In the period, private equity group GTCR
announced it was considering an all-cash approach for
the company. While the shares rallied at this point,
GTCR then stepped away from the transaction. Water
Intelligence, a multi-national leak detection and
remediation company, fell 33% over the period
despite solid financial and operational performance.
Fallers included two other healthcare companies.
Aptamer, a developer of aptamer and optimer binders for
the life sciences industry, fell 71% over the period. During
2022, market sentiment turned against loss making
companies, and the company felt the effects of this
despite trading continuing as expected. However, an
update in early January has pointed to a deterioration in
end-markets and customers either delaying project starts
or extending decision making cycles. Whilst expectations
have been re-set, no order or project has been cancelled
and the company continues to add to its pipeline. Angle,
a liquid biopsy company, finally received FDA approval
in May for its Parsortix device. However, the pace of
commercialisation has been slower than market
expectations. A trading update in early January pointed
to slower sales conversion than had been hoped for
based on the depth of the pipeline and shares fell 74%.
There were three real disappointments amongst the
newer holdings. Flylogix, which established a methane
emissions detection service for North Sea oil and gas
companies using drones, found good demand from
customers, but proved unable to establish reliable
and consistent operations, so had to be substantially
written down. Glantus, a provider of accounts payable
automation and analytics, had a disastrous start to life
as a public company, with a badly handled company
re-organisation to move back office functions to Costa
Rica, albeit a move which will drive value in the longer
run. The poor handling led to a sharp fall in revenues
during the process, which is now complete. However,
the losses, combined with gearing in the company led
to a dramatic fall in the share price. Clean Power
Hydrogen (“CPH2”), which is commercialising a
membrane free electrolyser technology, has delayed
the launch of its product due to design flaws emerging
during the commissioning process of the first units.
Portfolio Activity
The Company made five new investments and four
follow-on investments during the period. The new
investments comprised four Initial Public Offerings
(“IPOs”), and one pre-IPO investment.
The IPOs in the first part of the year were CPH2
and Strip Tinning (“ST”), which have so far been
disappointing investments, and EnSilica, which has
performed strongly. The CPH2 electrolyser design
avoids the problem of thin membrane degradation in
PEM (proton-electrolyte membrane) electrolysers, which
limits useful life, but at the cost of needing to manage
the mixed gasses through a cryogenic circuit for
separation. Key advantages of the CPH2 system include
long system life, 40% less water usage, high purity
levels of the output gasses, and the avoidance of
expensive process catalysts. These benefits should
make CPH2’s system cost competitive at low volumes.
Unfortunately, during commissioning of the initial scaled
up units, the company uncovered some design issues,
which have required a period of further engineering
and design work, delaying the company’s progress.
ST is a market leader in the provision of high-performance
electronic connector products and design services to the
automotive industry. It manufactures flexible printed
circuit, flat foil, cable and busbar connectors, which
are used in car heating and lighting applications. This
business dates back to the 1950s and ST has very long-
term relationships with vehicle manufacturers and prime
contractors, which positions it well for expansion into
growth markets. The company floated to raise funding for
two opportunities. Firstly, the growing demand for more
sophisticated connectors driven by greater functionality
being embedded into automotive glazing. This will involve
invisible heating, rain and autonomous driving sensors,